Infliximab for ulcerative colitis: The need for adequately powered placebo-controlled trials

American Journal of Gastroenterology

Volumn 97, Issue 10, 2002, Pages 2488-2489

  Rutgeerts, P ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; STEROID;

CLINICAL TRIAL; COLITIS; COLON RESECTION; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; REMISSION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0036792703     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04407-6     Document Type: Editorial

References (7)

1. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577-84.
2. Chey WY, Hussain A, Ryan C, et al. Infliximab is an effective therapeutic agent for ulcerative colitis. Am J Gastroenterol 2000;95:A2530-A2531 (abstract).
3. Present DH. Infliximab therapy for ulcerative colitis: Many unanswered questions. Am J Gastroenterol 2001;96:2294-6.
4. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflammatory Bowel Dis 2001;7(suppl 1):S30-S33.
5. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis. A pilot study. Wien Klin Wochenschr 2001;113:930-3.
6. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflammatory Bowel Dis 2001;7:83-8.
7. Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in steroid-resistant ulcerative colitis: A randomized controlled trial. Gastroenterology 2002:122:A-99.